Rosanne Sprute

Rosanne Sprute

Auto-generated profile, based on publicly available information

Rosanne Sprute

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
MHMartin Hoenigl
Martin Hoenigl
DSDanila Seidel
Danila Seidel
RSRosanne Sprute
Rosanne Sprute
CCCristina Cunha
Cristina Cunha
MOMatteo Oliverio
Matteo Oliverio
ACAgostinho Carvalho
Agostinho Carvalho

29 February 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
RARitesh Agarwal
Ritesh Agarwal
ISInderpaul Sehgal
Inderpaul Sehgal
VMValliappan Muthu
Valliappan Muthu
DDDavid W. Denning
David W. Denning
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
AAAshutosh N. Aggarwal
Ashutosh N. Aggarwal
Background: The International Society for Human and Animal Mycology (ISHAM) working group proposed recommendations for managing allergic bronchopulmonary aspergillosis (ABPA) a decade ago. There is a need to update these recommendations due to advances in diagnostics and therapeutics.Methods: An international expert group was convened to develop guidelines for managing ABPA (caused byAspergillusspp.) and allergic bronchopulmonary mycosis (ABPM; caused by fungi other thanAspergillusspp.) in adults and children using a modified Delphi method (two online rounds and one in-person meeting). We defined consensus as ≥70% agreement or disagreement. The terms “recommend” and “suggest” are used when the consensus was ≥70% and <70%, respectively.Results: We recommend screening forA. fumigatussensitisation using fungus-specific IgE in all newly diagnosed asthmatic adults at tertiary care but only difficult-to-treat asthmatic children. We recommend diagnosing ABPA in those with predisposing conditions or compatible clinico-radiological presentation, with a mandatory demonstration of fungal sensitisation and serum total IgE ≥500 IU·mL−1and two of the following: fungal-specific IgG, peripheral blood eosinophilia or suggestive imaging. ABPM is considered in those with an ABPA-like presentation but normalA. fumigatus-IgE. Additionally, diagnosing ABPM requires repeated growth of the causative fungus from sputum. We do not routinely recommend treating asymptomatic ABPA patients. We recommend oral prednisolone or itraconazole monotherapy for treating acute ABPA (newly diagnosed or exacerbation), with prednisolone and itraconazole combination only for treating recurrent ABPA exacerbations. We have devised an objective multidimensional criterion to assess treatment response.Conclusion: We have framed consensus guidelines for diagnosing, classifying and treating ABPA/M for patient care and research.

19 March 2024 in The Lancet Microbe
Verified
Journal Article
Open access
DSDanila Seidel
Danila Seidel
SWSebastian Wurster
Sebastian Wurster
JJJeffrey D Jenks
Jeffrey D Jenks
HSHatim Sati
Hatim Sati
JGJean-Pierre Gangneux
Jean-Pierre Gangneux
DKDimitrios P Kontoyiannis
Dimitrios P Kontoyiannis
The effects of climate change and natural disasters on fungal pathogens and the risks for fungal diseases remain incompletely understood. In this literature review, we examined how fungi are adapting to an increase in the Earth's temperature and are becoming more thermotolerant, which is enhancing fungal fitness and virulence. Climate change is creating conditions conducive to the emergence of new fungal pathogens and is priming fungi to adapt to previously inhospitable environments, such as polluted habitats and urban areas, leading to the geographical spread of some fungi to traditionally non-endemic areas. Climate change is also contributing to increases in the frequency and severity of natural disasters, which can trigger outbreaks of fungal diseases and increase the spread of fungal pathogens. The populations mostly affected are the socially vulnerable. More awareness, research, funding, and policies on the part of key stakeholders are needed to mitigate the effects of climate change and disaster-related fungal diseases.

5 September 2014 in Leukemia
Verified
Journal Article
Closed access
PDF file
IVI Vater
I Vater
MMM Montesinos-Rongen
M Montesinos-Rongen
MSM Schlesner
M Schlesner
AHA Haake
A Haake
FPF Purschke
F Purschke
RSR Siebert
R Siebert

13 June 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJannik Stemler
Jannik Stemler
SMSibylle Mellinghoff
Sibylle Mellinghoff
YKYascha Khodamoradi
Yascha Khodamoradi
RSRosanne Sprute
Rosanne Sprute
ACAnnika Y Classen
Annika Y Classen
DTDaniel Teschner
Daniel Teschner
Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. 7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients. Novel treatment options in HM, such as CAR-T-cell treatment or novel targeted therapies for acute myeloid leukaemia (AML) were considered, however, data are insufficient to give general recommendations for routine antifungal prophylaxis in these patients. Major changes regarding specific recommendations compared to the 2017 edition are the now moderate instead of mild support for the recommendations of isavuconazole and voriconazole. Furthermore, published evidence on micafungin allows recommending it at moderate strength for its use in HM. For the first time we included recommendations for non-pharmaceutical measures regarding IFD, comprising the use of high-efficiency particulate air (HEPA) filters, smoking, measures during construction work and neutropenic diets.We reviewed the impact of antifungal prophylaxis with triazoles on drug–drug interactions with novel targeted therapies that are metabolized via cytochrome p450 where triazoles inhibit CYP3A4/5. The working group recommends reducing the dose of venetoclax when used concomitantly with strong CYP3A4 inhibiting antifungals. Furthermore, we reviewed data on the prophylactic use of novel antifungal agents. Currently there is no evidence to support their use in a prophylactic setting in clinical practice.

18 February 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
RSRosanne Sprute
Rosanne Sprute
JSJon Salmanton-García
Jon Salmanton-García
ESErtan Sal
Ertan Sal
XMXhorxha Malaj
Xhorxha Malaj
ZRZdeněk Ráčil
Zdeněk Ráčil
TGthe FungiScope® ECMM/ISHAM Working Group
the FungiScope® ECMM/ISHAM Working Group
To provide a basis for clinical management decisions in Purpureocillium lilacinum infection. Unpublished cases of invasive P. lilacinum infection from the FungiScope® registry and all cases reported in the literature were analysed. We identified 101 cases with invasive P. lilacinum infection. Main predisposing factors were haematological and oncological diseases in 31 cases (30.7%), steroid treatment in 27 cases (26.7%), solid organ transplant in 26 cases (25.7%), and diabetes mellitus in 19 cases (18.8%). The most prevalent infection sites were skin (n = 37/101, 36.6%) and lungs (n = 26/101, 25.7%). Dissemination occurred in 22 cases (21.8%). Pain and fever were the most frequent symptoms (n = 40/101, 39.6% and n = 34/101, 33.7%, respectively). Diagnosis was established by culture in 98 cases (97.0%). P. lilacinum caused breakthrough infection in 10 patients (9.9%). Clinical isolates were frequently resistant to amphotericin B, whereas posaconazole and voriconazole showed good in vitro activity. Susceptibility to echinocandins varied considerably. Systemic antifungal treatment was administered in 90 patients (89.1%). Frequently employed antifungals were voriconazole in 51 (56.7%) and itraconazole in 26 patients (28.9%). Amphotericin B treatment was significantly associated with high mortality rates (n = 13/33, 39.4%, P = <0.001). Overall mortality was 21.8% (n = 22/101) and death was attributed to P. lilacinum infection in 45.5% (n = 10/22). P. lilacinum mainly presents as soft-tissue, pulmonary or disseminated infection in immunocompromised patients. Owing to intrinsic resistance, accurate species identification and susceptibility testing are vital. Outcome is better in patients treated with triazoles compared with amphotericin B formulations.